Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Radiologically confirmed brain metastases from Non Small Cell Lung Cancer

• No symptoms due to brain metastases

• No previous radiotherapy treatment for the Brain metastases

Exclusion Criteria:

• No prior chemotherapy

• No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ

• Any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease)